Improving the understanding of originator and biosimilar biologics among healthcare providers in Saudi Arabia

The loss of patentability of many originator biologics has led to the rapid introduction of biosimilar agents. The anticipated economic benefit of introducing such agent has been accompanied by vagueness surrounding their biotechnology, approval requirements, positioning in treatment paradigms and p...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Saudi Pharm J
Glavni autori: Omair, Mohammed A., Alhawassi, Tariq, Alwaihibi, Munira, Aldrees, Ghada, Mosli, Mahmoud, Asser, Wesam M., Alharaibi, Maryam A., Alotaibi, Atheer T., Bintaleb, Doaa A., Alharbi, Najah K., Alotaibi, Ahmed Z., Alshammari, Wajed A., Alanazi, Nouf, Asiri, Ali M., Almadany, Rana, Al Rayes, Hanan, Al-Thunian, Turki, Alotaibi, Moureq, Al Jazaeri, Abdulrazaq
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7783213/
https://ncbi.nlm.nih.gov/pubmed/33424270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jsps.2020.11.008
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items